Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Research & Development (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Research & Development for 13 consecutive years, with $150.2 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 262.76% year-over-year to $150.2 million; the TTM value through Mar 2026 reached $453.7 million, up 281.49%, while the annual FY2025 figure was $345.0 million, 239.38% up from the prior year.
  • Research & Development hit $150.2 million in Q1 2026 for Viking Therapeutics, down from $153.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $153.5 million in Q4 2025 and bottomed at $11.0 million in Q1 2023.
  • Average Research & Development over 5 years is $42.0 million, with a median of $22.8 million recorded in 2024.
  • Year-over-year, Research & Development dropped 12.32% in 2023 and then surged 395.24% in 2025.
  • Viking Therapeutics' Research & Development stood at $16.2 million in 2022, then increased by 26.73% to $20.5 million in 2023, then skyrocketed by 51.14% to $31.0 million in 2024, then soared by 395.24% to $153.5 million in 2025, then dropped by 2.16% to $150.2 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $150.2 million, $153.5 million, and $90.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.